-
As Psilocybin Trials Face Delays, Compass Pathways (CMPS) Cuts Workforce To Conserve Cash
Thursday, October 31, 2024 - 2:30pm | 744Read More...Compass Pathways (NASDAQ:CMPS) has announced delays for two key Phase 3 clinical trials involving its psilocybin program, widely seen as a leader in the psychedelic drug development space. As Endpoint News reported, the unexpected timeline shifts, unveiled in the company's third-quarter earnings...
-
Novo Nordisk's Once-Weekly Insulin Icodec Shows Favorable Reduction In HbA1c In Type 2 Diabetes
Thursday, April 28, 2022 - 2:44pm | 252Read More...Novo Nordisk A/S (NYSE: NVO) has announced topline results from Phase 3a ONWARDS 2 trial, 26-week efficacy and safety treat-to-target trial investigating once-weekly insulin icodec vs. insulin degludec. The study included 526 people with type 2 diabetes switching from daily insulin...
-
InflaRx Secures €44M Grant From German Govt To Advance Its COVID-19 Trial
Tuesday, October 19, 2021 - 3:42pm | 292Read More...The German Ministry of Education & Research and the Ministry of Health have granted €43.7 million to InflaRx N.V. (NASDAQ: IFRX) to support the development of vilobelimab for COVID-19 patients. The grant was awarded as part of a government initiative, which the German...
-
AbbVie Presents New Upadacitinib Data In Atopic Dermatitis
Thursday, September 30, 2021 - 3:04pm | 203Read More...AbbVie Inc (NYSE: ABBV) announced new analyses from the Phase 3 Rinvoq (upadacitinib) atopic dermatitis clinical trial program. Data were presented at the European Academy of Dermatology and Venereology (EADV) Virtual Congress. One analysis showed a greater proportion of patients...
-
Pfizer-BioNTech COVID-19 Shot Safe, Effective Through Six Months After Second Dose
Thursday, April 1, 2021 - 7:33am | 333Read More...Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) have announced updated topline results from analysis of 927 confirmed symptomatic cases of COVID-19 observed in Phase 3 study through March 13. Data showed that the vaccine, BNT162b2, was 91.3% effective...
-
Chiasma's Mycapssa Improves Acromegaly Related Symptoms After Switching From iSRLs
Monday, March 22, 2021 - 8:42am | 275Read More...Chiasma Inc (NASDAQ: CHMA) has announced new data from the MPOWERED Phase 3 trial of Mycapssa as the first oral therapy to treat acromegaly. Chiasma presented the data at the Endocrine Society's annual meeting. The data from MPOWERED showed that Mycapssa improved clinical...
-
Strongbridge Biopharma Stock Trading Higher On Detailed Recorlev Data In Cushing's Syndrome
Monday, March 22, 2021 - 8:04am | 311Read More...Strongbridge Biopharma plc (NASDAQ: SBBP) has announced detailed results from the previously reported Phase 3 LOGICS study of Recorlev (levoketoconazole) in patients with endogenous Cushing's syndrome. Data were presented at the Annual Meeting of the Endocrine Society. The...
-
Ocuphire Pharma Stock Is Trading Higher After Nyxol Aces Late-Stage Study
Monday, March 15, 2021 - 6:38am | 311Read More...Ocuphire Pharma Inc (NASDAQ: OCUP) stock is soaring in the premarket in reaction to positive data from MIRA-2 Phase 3 trial evaluating Nyxol. Nyxol is an eye drop formulation of phentolamine mesylate designed to reverse pharmacologically induced mydriasis (dilation of...
-
PhaseBio Recruits BioVectra As Manufacturing Partner For Bentracimab
Thursday, March 11, 2021 - 12:11pm | 185Read More...PhaseBio Pharmaceuticals Inc (NASDAQ: PHAS) has signed BioVectra as its manufacturing partner for its bentracimab as it ushers the drug through Phase 3. PhaseBio licensed bentracimab from AstraZeneca plc (NASDAQ: AZN), the maker of blood thinner Brilinta (ticagrelor), in 2017....
-
Roche's Tocilizumab, Gilead's Remdesivir Combo Fails To Improve Hospital Discharge Time in COVID-19 Study
Thursday, March 11, 2021 - 7:37am | 469Read More...Roche Holdings AG (OTCQX: RHHBY) has announced data from Phase 3 REMDACTA trial evaluating Actemra/RoActemra (tocilizumab) plus Gilead Sciences Inc's (NASDAQ: GILD) Veklury (remdesivir). The study did not meet the primary endpoint of improved time...
-
Vir/GSK's COVID-19 Antibody Therapy Cuts Hospitalization, Deaths by 85%, Seeks FDA Emergency Use Nod
Thursday, March 11, 2021 - 6:13am | 341Read More...An Independent Data Monitoring Committee (IDMC) has recommended that the Phase 3 COMET-ICE trial, evaluating VIR-7831 (GSK4182136) as monotherapy for COVID-19, stop enrollment due to evidence of profound efficacy. The antibody treatment is being developed under a collaboration between...
-
Eli Lilly's Tirzepatide Tops Novo's Semaglutide In Late-Stage Diabetes Study
Thursday, March 4, 2021 - 12:40pm | 486Read More...Eli Lilly & Co (NYSE: LLY) has reported positive results from another Phase 3 trial evaluating tirzepatide in Type 2 diabetics. The dual GIP/GLP-1 agonist beat Novo Nordisk A/S’s (NYSE: NVO) semaglutide against multiple measures. Recently, Lilly...
-
Vascular Biogenics' Ovarian Cancer Gene Therapy Shows Response Rate Of Over 58%
Thursday, March 4, 2021 - 9:28am | 245Read More...Vascular Biogenics Ltd (NASDAQ: VBLT) announced positive results of the pre-specified interim analysis of the Phase 3 OVAL study of VB-111 (ofranergene obadenovec) in recurrent platinum-resistant ovarian cancer. VB-111 (ofranergene obadenovec) is an anti-cancer gene-...
-
BioXcel's BXCL501 Lower Dose Shows Statistical Significance On Agitation Scales
Wednesday, March 3, 2021 - 10:49am | 297Read More...BioXcel Therapeutics Inc (NASDAQ: BTAI) plans to finalize study design, dosing, and endpoints for its BXCL501 Phase 3 program in dementia-related agitation. The end of the Phase 2 meeting with the FDA is scheduled in Q2 2021. BXCL501 is an orally dissolving thin film formulation of...
-
Eli Lilly/Incyte's Baricitinib Shows Benefit In Patchy Hair Loss Disorder
Wednesday, March 3, 2021 - 10:43am | 297Read More...Eli Lilly and Co (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announces top-line results from Phase 3 BRAVE-AA2 study evaluating baricitinib 2-mg and 4-mg in adults with severe alopecia areata (AA). AA is an autoimmune disorder that usually results in...
